Even though, the small sample size constrained our ability to provide a statistically significant correlation with all fibrosis stages, our results if validate in other cohorts could reinforce the relevance of GDF11 as therapeutic target to reduce NAFLD-associated liver damage. This evidence concerns the gene GDF11 and metabolic dysfunction-associated steatotic liver disease.